Cargando…
ErbB2 enhances mammary tumorigenesis, oncogene-independent recurrence and metastasis in a model of IGF-IR-mediated mammary tumorigenesis
BACKGROUND: The type I insulin-like growth factor receptor (IGF-IR) and ErbB2 (Her-2) are receptor tyrosine kinases implicated in human breast cancer. Both proteins are currently the subject of targeted therapeutics that are used in the treatment of breast cancer or which are in clinical trials. The...
Autores principales: | Campbell, Craig I, Petrik, James J, Moorehead, Roger A |
---|---|
Formato: | Texto |
Lenguaje: | English |
Publicado: |
BioMed Central
2010
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC2940847/ https://www.ncbi.nlm.nih.gov/pubmed/20825649 http://dx.doi.org/10.1186/1476-4598-9-235 |
Ejemplares similares
-
IGF-IR Mediated Mammary Tumorigenesis Is Enhanced during Pubertal Development
por: Jones, Robert A., et al.
Publicado: (2014) -
A moderate elevation of circulating levels of IGF-I does not alter ErbB2 induced mammary tumorigenesis
por: Dearth, Robert K, et al.
Publicado: (2011) -
Mammary Cells with Active Wnt Signaling Resist ErbB2-Induced Tumorigenesis
por: Bu, Wen, et al.
Publicado: (2013) -
The glucose transporter GLUT1 is required for ErbB2-induced mammary tumorigenesis
por: Wellberg, Elizabeth A., et al.
Publicado: (2016) -
Selective Roles of E2Fs for ErbB2- and Myc-mediated Mammary Tumorigenesis
por: Wu, Lizhao, et al.
Publicado: (2013)